Description:
Primary Objective Dose Escalation:
To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors
and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
Primary Objective Dose Expansion:
To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract
Cancer (BTC), patients with advanced pancreatic neuroendocrine tumors (pNETs), patients with
locally advanced, unresectable, metastatic extra-pancreatic neuroendocrine tumors (EP-NETs),
and patients with soft tissue sarcomas (STS) treated at a dose of 300 mg QD.
Secondary Objective:
To evaluate the pharmacokinetic profile of multiple dose surufatinib in patients with
advanced solid tumors and to evaluate the anti cancer activity of surufatinib in patients
with advanced solid tumors.
Title
- Brief Title: A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
- Official Title: A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Surufatinib (HMPL-012), Previously Named Sulfatinib in Advanced Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
2015-012-00US1
- NCT ID:
NCT02549937
Conditions
Interventions
Drug | Synonyms | Arms |
---|
surufatinib | HMPL-012, sulfatinib | Escalation 100mg |
Purpose
Primary Objective Dose Escalation:
To evaluate the safety and tolerability of surufatinib in patients with advanced solid tumors
and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
Primary Objective Dose Expansion:
To evaluate the anticancer activity of surufatinib in patients with advanced Biliary Tract
Cancer (BTC), patients with advanced pancreatic neuroendocrine tumors (pNETs), patients with
locally advanced, unresectable, metastatic extra-pancreatic neuroendocrine tumors (EP-NETs),
and patients with soft tissue sarcomas (STS) treated at a dose of 300 mg QD.
Secondary Objective:
To evaluate the pharmacokinetic profile of multiple dose surufatinib in patients with
advanced solid tumors and to evaluate the anti cancer activity of surufatinib in patients
with advanced solid tumors.
Detailed Description
The study is an open-label, dose escalation and expansion clinical trial of surufatinib
orally once daily (QD) in patients with advanced solid tumors.
The study consists of two phases:
Dose escalation phase - A 3+3 design will be used for this portion of the study.
- Approximately 15 to 35 evaluable patients will be enrolled. The actual number of
patients depends on the Dose-limiting toxicity (DLT) situation as well as the RP2D dose
level reached in this trial.
- The trial will approximately evaluate five surufatinib dose levels at 50,100, 200, 300
and 400 mg/day.
Expansion phase:
Approximately 105 patients will be enrolled into one of four open-label treatment arms during
this phase: at least 30 patients with advanced BTC that has progressed on standard first-line
chemotherapy will be assigned to Arm A, at least 15 patients with advanced pNET that has
progressed on either everolimus, sunitinib, or both will be assigned to Arm B, at least 15
patients with advanced EP-NET that has progressed on everolimus will be assigned to Arm C,
and at least 45 patients with Soft Tissue Sarcoma will be assigned to Arm D. Subjects
enrolled in this phase are to be evaluated for the safety, tolerability and pharmacokinetic
(PK) characteristics to confirm the selected surufatinib dose.
Subjects will receive surufatinib daily treatment continuously with every 28-day treatment
cycle until disease progression, death, or intolerable toxicity at the investigator's
discretion for a favorable benefit to risk balance.
Trial Arms
Name | Type | Description | Interventions |
---|
Escalation 50 mg | Experimental | Escalation cohort at 50 mg/day | |
Escalation 100mg | Experimental | Escalation cohort at 100 mg/day | |
Escalation 200 mg | Experimental | Escalation cohort at 200 mg/day | |
Escalation 300 mg | Experimental | Escalation cohort at 300 mg/day | |
Escalation 400 mg | Experimental | Escalation cohort at 400 mg/day | |
Expansion | Experimental | Subjects will receive RP2D surufatinib daily treatment continuously with every 28-day treatment cycle. Four expansion cohorts will enroll BTC, pNET, EP-NET, and STS patients, respectively. | |
Eligibility Criteria
Key Inclusion Criteria:
- Fully understand the study and voluntarily sign the informed consent form;
- At least 18 years old;
- Histologically or cytologically documented, locally advanced or metastatic solid
malignancy of any type during the dose escalation phase, that has progressed on
available standard systemic therapy, and for whom no effective therapy or standard of
care exists; and locally advanced or metastatic BTC that has progressed on standard
first-line chemotherapy; locally advanced or metastatic pNET that has progressed on
everolimus, sunitinib or both; locally advanced or metastatic EP-NET that has
progressed on everolimus; advanced STS that has progressed on at least one line of
standard therapy or refused standard frontline cytotoxic chemotherapy during the
expansion phase;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
- Hypertension that is not controlled by antihypertension medication, defined as:
systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg;
- History or presence of digestive tract diseases, including active gastric/duodenal
ulcer or ulcerative colitis, or active hemorrhage of an unresected gastrointestinal
tumor, or an evaluation by investigators of having any other condition that could
possibly result in gastrointestinal tract hemorrhage or perforation;
- History or presence of serious hemorrhage , hemoptysis or hematemesis within 3 months
or a thromboembolic event (including Deep Vein Thrombosis (DVT), stroke and/or
transient ischemic attack) within 6 months;
- Patients with squamous Non Small Cell Lung Cancer (NSCLC) should be excluded;
- Clinically significant cardiovascular disease, including but not limited to, acute
myocardial infarction within 6 months prior to enrollment, severe/unstable angina
pectoris or coronary artery bypass grafting, New York Heart Association Class III/IV
congestive heart failure, ventricular arrhythmias requiring treatment or left
ventricular ejection fraction (LVEF) < 50%;
- Systemic anti-neoplastic therapies within 4 weeks prior to the initiation of
investigational treatment, including chemotherapy, radical radiotherapy,
hormonotherapy, biotherapy and immunotherapy;
- Palliative radiotherapy for bone metastasis/lesion within 2 weeks;
- Known Human immunodeficiency virus (HIV) infection;
- Known clinically significant history of liver disease, including viral or other
hepatitis, current alcohol abuse, or cirrhosis;
- Women who are pregnant or lactating;
- Brain metastases and/or spinal cord compression untreated with surgery and/or
radiotherapy, and without clinical imaging evidence of stable disease for 14 days or
longer; Subjects requiring steroids within 4 weeks prior to start of study treatment
will be excluded;
- Inability to take medication orally, dysphagia or an active gastric ulcer resulting
from previous surgery or a severe gastrointestinal disease, or any other condition
that investigators believe may affect absorption of the investigational product;
- Received investigational treatment in another clinical study within 4 weeks prior to
the initiation of investigational treatment;
- Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory
result, or any other condition that investigators suspect may prohibit use of the
investigational product, affect interpretation of study results, or put the patient at
high risk.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of DLT |
Time Frame: | From date of enrollment through end of Cycle 1, up to 28 days |
Safety Issue: | |
Description: | The primary outcome during dose escalation will be the incidence rate of DLTs |
Secondary Outcome Measures
Measure: | maximum plasma concentration calculated with Blood samples |
Time Frame: | within 30 days after the first dose |
Safety Issue: | |
Description: | Blood samples will be taken to measure the levels of study drug. |
Measure: | time to reach maximum concentration calculated with Blood samples |
Time Frame: | within 30 days after the first dose |
Safety Issue: | |
Description: | Blood samples will be taken to measure the levels of study drug |
Measure: | Objective response rate |
Time Frame: | within 30 days after the last dose |
Safety Issue: | |
Description: | the proportion of subjects who have a Complete Response or Partial Response |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Hutchison Medipharma Limited |
Trial Keywords
- biliary
- pancreatic
- neuroendocrine
- carcinoid
- PNET
- EP-NET
- extrapancreatic
- sarcoma
- soft tissue sarcoma
- STS
- BTC
Last Updated
June 14, 2021